|
US5908825A
(en)
*
|
1997-01-09 |
1999-06-01 |
University Of Maryland At Baltimore |
Dosage composition for nasal delivery and method of use of the same
|
|
US6458925B1
(en)
|
1998-08-03 |
2002-10-01 |
University Of Maryland, Baltimore |
Peptide antagonists of zonulin and methods for use of the same
|
|
DE69912441T2
(de)
|
1998-08-19 |
2004-08-19 |
Skyepharma Canada Inc., Verdun |
Injizierbare wässerige propofoldispersionen
|
|
AU754142B2
(en)
*
|
1998-09-14 |
2002-11-07 |
University Of Maryland At Baltimore |
Method of using zot or zonulin to inhibit lymphocyte proliferation in an antigen-specific manner
|
|
US6733762B1
(en)
|
1998-09-14 |
2004-05-11 |
University Of Maryland, Baltimore |
Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner
|
|
MXPA02003176A
(es)
|
1999-10-04 |
2002-09-30 |
Shearwater Corp |
Neuropeptidos estabilizados por polimero.
|
|
AU2001249067A1
(en)
*
|
2000-05-19 |
2001-12-03 |
University Of Maryland, Baltimore |
Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
|
|
US7034036B2
(en)
*
|
2000-10-30 |
2006-04-25 |
Pain Therapeutics, Inc. |
Inhibitors of ABC drug transporters at the blood-brain barrier
|
|
EP1384468A1
(de)
*
|
2002-07-25 |
2004-01-28 |
Cognis France S.A. |
Verfahren zum Schutz und zur Modulation von Tight Junctions
|
|
EP1384469A1
(de)
*
|
2002-07-25 |
2004-01-28 |
Cognis France S.A. |
Verfahren zum Schutz und zur Modulation von Tight Junctions
|
|
EP1648917A4
(en)
*
|
2003-07-15 |
2008-11-12 |
Univ Maryland |
AGONISTPOLYPEPTIDE OF THE RECEPTOR FOR ZOT AND ZONULIN
|
|
US20080038843A1
(en)
*
|
2006-08-11 |
2008-02-14 |
University Of Maryland - Baltimore |
Method of diagnosing celiac disease
|
|
TW200637573A
(en)
*
|
2005-01-14 |
2006-11-01 |
Univ Maryland |
Peptide for delivery of mucosal vaccines
|
|
AR057058A1
(es)
*
|
2005-06-09 |
2007-11-14 |
Alba Therapeutics Corp |
Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
|
|
ES2459018T3
(es)
*
|
2006-02-09 |
2014-05-07 |
Alba Therapeutics Corporation |
Formulaciones de efectores de la unión estrecha
|
|
US20070239520A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Devin Collins |
Motivational apparatus and method of motivation
|
|
WO2008043107A2
(en)
*
|
2006-10-06 |
2008-04-10 |
Alba Therapeutics Corporation |
Use of tight junction antagonists to treat inflammatory bowel disease
|
|
US8034776B2
(en)
*
|
2006-10-26 |
2011-10-11 |
Alba Therapeutics Corporation |
Materials and methods for the treatment of celiac disease
|
|
US20100144646A1
(en)
*
|
2006-11-03 |
2010-06-10 |
Blake Paterson |
Method of diagnosing and treating asthma
|
|
US8728491B2
(en)
*
|
2007-05-07 |
2014-05-20 |
Alba Therapeutics Corporation |
Transcutaneous delivery of therapeutic agents
|
|
US20110201543A1
(en)
*
|
2007-06-29 |
2011-08-18 |
Blake Paterson |
Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
|
|
US8198233B2
(en)
|
2007-07-26 |
2012-06-12 |
Alba Therapeutics Corporation |
Synthetic peptides that enhance tight junction permeability
|
|
RU2639483C2
(ru)
|
2012-03-19 |
2017-12-21 |
Сидара Терапьютикс, Инк. |
Режимы дозирования для соединений класса эхинокандинов
|
|
JP6760657B2
(ja)
*
|
2015-05-26 |
2020-09-23 |
国立大学法人東海国立大学機構 |
タイトジャンクションの緩和剤、該緩和剤を含む薬剤吸収補助剤、及び該緩和剤を含む医薬組成物
|
|
CA3052975A1
(en)
|
2017-02-10 |
2018-08-16 |
Innovate Biopharmaceuticals, Inc. |
Compositions and methods for treating disease associated with permeability of intestinal epithelium
|
|
US11608359B2
(en)
|
2018-02-23 |
2023-03-21 |
9 Meters Biopharma, Inc. |
Compounds and methods for treating tight junction permeabtility
|